MediPharm Labs Corp.

Ladies and gentlemen, thank you for standing by and welcome to the Medifarm Labs fourth quarter and fiscal 2021 financial results conference call. Please be advised that today's conference is being recorded. Before we begin, please note the following caution respecting forward-looking statements, which is made on behalf of Medifarm Labs and all of its representatives on this call. Statements made on this call will contain forward-looking information that involve risks and uncertainties. Actual results could differ materially from a conclusion, forecast or projection in the forward-looking information. Certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. Additional information about the material factors that could cause actual results to differ materially from the conclusions, forecasts or projections in the forward-looking information. and the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, as reflected in the forward-looking information, are contained in Medifarm Labs filings with the Canadian and provincial security regulators, which are available on the CDAR website at cdar.com. I will now pass the call to Brian Howcroft, CEO of Medifarm.

Please go ahead.

Thank you, Operator, and good morning, everyone. We appreciate you joining us for Medifarm's Q4 and fiscal 2021 financial results conference call. Joining me on the call today are Keith Strong, Medifarm's president, and Greg Hunter, the company's CFO. As most of you know, I joined Medifarm as CEO in late November of last year. At that time, I saw a company with all the attributes required to become a true leader in the global precision-based cannabinoid space. In the five months since joining, I've gotten to know the business and the team better. We are all very confident that Medifarm is well positioned to achieve leadership in this space. Every member of our team would certainly acknowledge that the pharma opportunity is long-term in nature. However, it is our belief that there are very few companies in existence today that have the appropriate licensing and sophistication to capitalize on these opportunities. We believe that Medifarm will benefit highly from exposure to what the team expects will be one of the most profitable, sustainable opportunities in the global cannabinoid space. As the company pursues this longer-term opportunity, our team continues to execute on short and mid-term avenues to growth and profitability, both in the international and domestic markets. During 2021, in a challenging environment, particularly on the domestic front, the Medifront team, led by Keith and Greg, executed against several important initiatives designed to set the company's course squarely toward these objectives. Before I pass the call over to Keith to provide additional granularity on the team's effort, we'd like to take the opportunity to thank all of our shareholders for their patience and ongoing support as the team continues to position the company to not only achieve its long-term objectives, but to generate shareholder value along the way. I will now pass the call over to Keith.